Literature for peptidase S01.231: urokinase-type plasminogen activator

(References are filtered for relevance to Structure. To remove the filter click here. See explanation.)

2019
1. Buckley,B.J., Majed,H., Aboelela,A., Minaei,E., Jiang,L., Fildes,K., Cheung,C.Y., Johnson,D., Bachovchin,D., Cook,G.M., Huang,M., Ranson,M. and Kelso,M.J.
   6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease
   Bioorg Med Chem Lett126753-126753. PubMed  Europe PubMed DOI  S  I
2017
2. Xue,G., Gong,L., Yuan,C., Xu,M., Wang,X., Jiang,L. and Huang,M.
   A structural mechanism of flavonoids in inhibiting serine proteases
   Food Funct8, 2437-2443. PubMed  Europe PubMed DOI  S  I
2016
3. Jiang,L., Andersen,L.M., Andreasen,P.A., Chen,L. and Huang,M.
   Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate
   Biochim Biophys Acta1860, 599-606. PubMed  Europe PubMed DOI  S  I
2014
4. Zhao,B., Xu,P., Jiang,L., Paaske,B., Kromann-Hansen,T., Jensen,J.K., Sorensen,H.P., Liu,Z., Nielsen,J.T., Christensen,A., Hosseini,M., Sorensen,K.K., Nielsen,N.C., Jensen,K.J., Huang,M. and Andreasen,P.A.
   A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility
   PLoS ONE9, e115872-e115872. PubMed  Europe PubMed DOI  S  I
2009
5. Jiang,L.G., Zhao,G.X., Bian,C.B., Yuan,C., Huang,Z.X. and Huang,M.D.
   Crystal structures of urokinase-type plasminogen activator in complex with 4-(aminomethyl)benzoic acid and 4-(aminomethyl-phenyl)-methanol
   Jiegou Huaxue28, 253-259.  S  I
2007
6. Zhao,G., Yuan,C., Wind,T., Huang,Z., Andreasen,P.A. and Huang,M.
   Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1
   J Struct Biol160, 1-10. PubMed  Europe PubMed DOI  S  I
2004
7. Wendt,M.D., Geyer,A., McClellan,W.J., Rockway,T.W., Weitzberg,M., Zhao,X., Mantei,R., Stewart,K., Nienaber,V., Klinghofer,V. and Giranda,V.L.
   Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors
   Bioorg Med Chem Lett14, 3063-3068. PubMed  Europe PubMed DOI  S  I
2003
8. [YEAR:18-4-2003]Zeslawska,E., Jacob,U., Schweinitz,A., Coombs,G., Bode,W. and Madison,E.
   Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors
   J Mol Biol328, 109-118. PubMed  Europe PubMed DOI  S  I
2001
9. Katz,B.A., Sprengeler,P.A., Luong,C., Verner,E., Elrod,K., Kirtley,M., Janc,J., Spencer,J.R., Breitenbucher,J.G., Hui,H., McGee,D., Allen,D., Martelli,A. and Mackman,R.L.
   Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets
   Chem Biol8, 1107-1121. PubMed  Europe PubMed DOI  S
2000
10. Katz,B.A., Mackman,R., Luong,C., Radika,K., Martelli,A., Sprengeler,P.A., Wang,J., Chan,H. and Wong,L.
    Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator
    Chem Biol7, 299-312. PubMed  Europe PubMed DOI  S
11. [YEAR:10-3-2000]Nienaber,V., Wang,J., Davidson,D. and Henkin,J.
    Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite
    J Biol Chem275, 7239-7248. PubMed  Europe PubMed DOI  S
12. [YEAR:11-8-2000]Zeslawska,E., Schweinitz,A., Karcher,A., Sondermann,P., Sperl,S., Sturzebecher,J. and Jacob,U.
    Crystals of the urokinase type plasminogen activator variant beta(c)-uPA in complex with small molecule inhibitors open the way towards structure-based drug design
    J Mol Biol301, 465-475. PubMed  Europe PubMed DOI  S  I
1995
13. Spraggon,G., Phillips,C., Nowak,U.K., Ponting,C.P., Saunders,D., Dobson,C.M., Stuart,D.I. and Jones,E.Y.
    The crystal structure of the catalytic domain of human urokinase-type plasminogen activator
    Structure3, 681-691. PubMed  Europe PubMed  S